AMRI Financial Facts
Loss from operations: 9.4MOther (expense) income, net: 452K
See Full Income Statement
Property and equipment, net: 132.88M
Total liabilities and stockholders' equity: 270M
See Full Balance Sheet
Earnings History for Albany Molecular Research Inc. (AMRI)
|
Expand Research on AMRI
| Next EPS Date | 7/31/13 *Est. | EPS Growth Rate | +1,050.0% *Last Qtr. |
|---|---|---|---|
| Average EPS % Beat Rate | +82.2% | Revenue Growth Rate | +10.6% *Last Qtr. |
| Average % Move 1-Wk after EPS | +13.4% |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Estimize EPS/Revs | Gd. | % Since | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 5/7/13 |
Q113 | $0.23 | N/A | N/A | $59.4M | $53.7M | N/A / N/A | = | -14.6% | Details | |
| 2/12/13 |
Q412 | $0.17 | $0.09 | +$0.08 | $59.1M | $56.49M | N/A / N/A | = | +84.6% | Details | |
| 11/6/12 |
Q312 | $0.00 | -$0.02 | +$0.02 | $55.8M | $50.8M | N/A / N/A | = | +202.9% | Details | |
| 8/1/12 |
Q212 | $0.06 | $0.02 | +$0.04 | $50M | $52M | N/A / N/A | = | +269.3% | Details | |
| 5/9/12 | Q112 | $0.02 | $0.05 | -$0.03 | $53.7M | $52.12M | N/A / N/A | = | +247.2% | Details | |
| 2/7/12 |
Q411 | -$0.19 | N/A | N/A | $46.6M | $48.6M | N/A / N/A | = | +238.2% | Details | |
| 11/8/11 |
Q311 | -$0.19 | N/A | N/A | $50.23M | $50.62M | N/A / N/A | = | +227.6% | Details | |
| 8/8/11 |
Q211 | -$0.02 | -$0.03 | +$0.01 | $53.9M | $52.42M | N/A / N/A | = | +139.7% | Details |
